Advertisement

The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff.

 

Follow us on Twitter @CIR_AACR!

From the Current Issue

  • Research Articles
    γδ T-cell Receptors Derived from Breast Cancer–Infiltrating T Lymphocytes Mediate Antitumor Reactivity
    Anke Janssen, Jose Villacorta Hidalgo, Dennis X. Beringer, Sanne van Dooremalen, Febilla Fernando, Eline van Diest, Antonela R. Terrizi, Peter Bronsert, Sylvia Kock, Annette Schmitt-Gräff, Martin Werner, Kerstin Heise, Marie Follo, Trudy Straetemans, Zsolt Sebestyen, Dmitry M. Chudakov, Sofya A. Kasatskaya, Felix E. Frenkel, Sarina Ravens, Eric Spierings, Immo Prinz, Ralf Küppers, Miroslav Malkovsky, Paul Fisch and Jürgen Kuball
    Cancer Immunol Res April 1 2020 8 (4) 530-543; DOI:10.1158/2326-6066.CIR-19-0513

    Proinflammatory γδ T cells infiltrate triple-negative breast cancers and are positioned in close proximity to tumor cells. T cells engineered to express paired TCRγ/TCRδ chains are tumor reactive against an array of tumor types.

  • Research Articles
    Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer
    Baosheng Chen, David M. Alvarado, Micah Iticovici, Nathan S. Kau, Haeseong Park, Parag J. Parikh, Dinesh Thotala and Matthew A. Ciorba
    Cancer Immunol Res April 1 2020 8 (4) 451-464; DOI:10.1158/2326-6066.CIR-19-0282

    Inhibition of the immune-metabolic enzyme IDO1 enhances radiation sensitivity in colorectal cancer and is radioprotective to the normal small intestine in mice. IDO1 inhibitors may increase radiation therapy effectiveness in humans with colorectal cancer while reducing intestinal toxicity.

  • Research Articles
    Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade
    Jeremy P. Snook, Ashleigh J. Soedel, H. Atakan Ekiz, Ryan M. O'Connell and Matthew A. Williams
    Cancer Immunol Res April 1 2020 8 (4) 506-517; DOI:10.1158/2326-6066.CIR-19-0690

    Checkpoint blockade enhances high-affinity T-cell responses to melanoma, but some patients do not benefit. Targeting SHP-1 expands the repertoire of T cells available to respond to treatment and induces antitumor activity from low-affinity T cells.

OnlineFirst Articles

Load more
Advertisement

Back to top